Twist Bioscience 8-K
PositiveEarningsNew guidanceImpairment / chargeLegal / investigation
AI drug discovery revenue assumption of $100M underpins FY2027 guidance for $550M–$560M in sales and positive adjusted EBITDA.
Filed 2026-11-12 07:19 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q4 and FY2026 results with Q1 and FY2027 guidance. Revenue growth accelerated to +27.9% Y/Y from +23.0% in Q3, with both DNA Synthesis and Protein Solutions and NGS Applications contributing.
Q1 FY2027 revenue midpoint of $131M is +3.4% Q/Q and +26.3% Y/Y vs Q4’s $126.6M; FY2027 revenue guidance is $550M-$560M (+21% Y/Y at the midpoint), assuming $100M in AI drug discovery revenue, with positive adjusted EBITDA.
Developments
- Products shipped to approximately 4,100 customers in FY2026, up from approximately 3,800 in FY2025.
- Physical gene shipments reached approximately 1.3M in FY2026, compared with approximately 938,000 in FY2025.
- Joined Lilly TuneLab as a provider of antibody characterization services.
- Launched Twist Express Screening Antibodies, an antibody screening product, and Twist MRD Express, custom molecular residual disease panels designed for turnaround as fast as one day.
Results with guidance
| Metric | Guided for Q4 FY2026 | Q4 FY2026 actual | Q1 FY2027 guide | FY2027 guide |
|---|---|---|---|---|
| Revenue | $456M-$457M | $459M (beat)+22% Y/Y | — | — |
| Revenue | $123M-$124M | $127M (beat)+28% Y/Y, +7.0% Q/Q | $130M-$132M+3.4% Q/Q at midpoint; +26% Y/Y at midpoint (better than reported) | $550M-$560M+21% Y/Y at midpoint |
| Gross margin | at least 52% | 52.4% (in line)+1.7 pp Y/Y | — | — |
| Gross margin | — | 53.1%+1.8 pp Y/Y, +0.3 pp Q/Q | — | 52.5%-53%+0.3 pp Y/Y at midpoint |
| AI drug discovery Revenue | — | — | — | $100M |
| Capital expenditures | — | — | — | $75M |
Earlier guidance from the 8-K filed 2026-08-03.
Results without guidance
| Metric | Q4 FY2026 | Change | FY2026 |
|---|---|---|---|
| Operating income | -$24.4M | vs -$29.9M Y/Y, vs -$36.3M Q/Q | -$139Mvs -$136M Y/Y |
| Net income | -$20.6M | vs -$27.1M Y/Y, vs -$35.1M Q/Q | -$130Mvs -$77.7M Y/Y |
| Diluted EPS | -$0.32 | vs -$0.45 Y/Y, vs -$0.56 Q/Q | -$2.08vs -$1.30 Y/Y |
| Cash and cash equivalents | $534M | +192% Y/Y, +355% Q/Q | — |
| Cash and marketable securities | $582M | +249% Q/Q | — |
| Diluted shares | 65.3M | +8.0% Y/Y, +4.6% Q/Q | 62.6M+4.7% Y/Y |
What moved the numbers
- Q4 revenue from DNA Synthesis and Protein Solutions was $61.0M, +33% Y/Y and +8% Q/Q; NGS Applications revenue was $65.7M, +24% Y/Y and +6% Q/Q. For FY2026, the segments generated $221.9M (+31.7%) and $237.5M (+14.1%), respectively.
- FY2026’s higher net loss alongside a nearly flat operating loss reflected a $48.8M gain on a business sale in FY2025 and $7.2M in FY2026 litigation settlement costs.
- Adjusted EBITDA (non-GAAP) was $2.2M in Q4, versus $(7.8)M a year earlier, and $(35.9)M for FY2026 versus $(46.9)M in FY2025. Stock-based compensation, the largest listed adjustment, was $19.5M in Q4 and $69.9M for FY2026.
- Net proceeds of approximately $425M were raised through an equity offering and at-the-market sales.
Other guidance (1)
| Metric | Period | Guidance |
|---|---|---|
| Adjusted EBITDA (non-GAAP) | FY2027 | positive |
Figures extracted from the filings and checked against their text; changes and verdicts computed from them.
The summary is written by an AI model reading the filing.
Model 005 · prompt v192 · 2026-11-12 15:39:09Z